	e:Mar. 16 th , 2022						
	· Name:Wei Wang						
Mar	uscript Title: Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin,						
and	and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial						
Mar	uscript number (if known): GS-22-161						
rela part to t	e interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are sed to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third ies whose interests may be affected by the content of the manuscript. Disclosure represents a commitment ansparency and does not necessarily indicate a bias. If you are in doubt about whether to list a cionship/activity/interest, it is preferable that you do so.						
	following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> uscript only.						
to t	author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains be epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive ication, even if that medication is not mentioned in the manuscript.						
	em #1 below, report all support for the work reported in this manuscript without time limit. For all other items, ime frame for disclosure is the past 36 months.						
	Name all entities with Specifications/Comments						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		T	1		
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
	•				
7	Support for attending	X None			
,	meetings and/or travel				
	meetings and/or traver				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	xNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
12		V None			
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None.		

		TENISE DISCEC	SOME I OMM
	e:Mar. 16 th , 2022	-	
	r Name:Lu Wang		
			inib in combination with nab-paclitaxel, doxorubicin,
			ingle-armed clinical trial
Mar	nuscript number (if known):	GS-	22-161
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a
	following questions apply touscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to tl		nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive manuscript.
	em #1 below, report all sup time frame for disclosure is	-	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	planning of the work
1	All support for the present	1	
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		

Time frame: past 36 months

_X__None

X__None

_X__None

2

3

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

any entity (if not indicated

		T	1		
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
	•				
7	Support for attending	X None			
,	meetings and/or travel				
	meetings and/or traver				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	xNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
12		V None			
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None.		

	a				
	e:Mar. 16 th , 2022	•			
	r Name: Jin-Yi Chang ouscript Title:	ovicity monitoring of nyro	tinib in combination with nab-paclitaxel, doxorubicin,		
			single-armed clinical trial		
		-	-22-161		
	-	-	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third		
	-		f the manuscript. Disclosure represents a commitment		
•	-	•	If you are in doubt about whether to list a		
	tionship/activity/interest, it				
The	following questions annly to	o the author's relationshir	os/activities/interests as they relate to the <u>current</u>		
	uscript only.	o the dutilor of clutionship	so, activities, interests as they relate to the <u>current</u>		
The	authawa nalatianahina/artiu	.itiaa/intavasta ahald ha	Jafinad byzadly. Far avancela if vary many regist neglector		
	• •	-	<u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive		
med	lication, even if that medica	tion is not mentioned in t	he manuscript.		
		·	I in this manuscript without time limit. For all other items,		
tne	time frame for disclosure is	the past 36 months.			
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate none (add rows as	institution)		
		needed)			
		Time frame: Since the initia	l planning of the work		
1	All support for the present	XNone			
	manuscript (e.g., funding, provision of study materials,				
	medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
		Time frame: pas	t 36 months		
2	Grants or contracts from	X None			
_	any entity (if not indicated				

in item #1 above).
Royalties or licenses

Consulting fees

X__None

X__None

		T	1		
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
	•				
7	Support for attending	X None			
,	meetings and/or travel				
	meetings and/or traver				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	xNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
12		V None			
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None.		

		ICIVITE DISCL	OSURE FURIVI
	e:Mar. 16 th , 2022 r Name:Fen Hu		
Mar and	nuscript Title: Cardiot cyclophosphamide in HER2-	oxicity monitoring of pyro positive breast cancer: a s	tinib in combination with nab-paclitaxel, doxorubicin, single-armed clinical trial
Mar	nuscript number (if known):	GS	-22-161
rela part to ti	ted to the content of your miles whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the current
to th med In it	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare tion is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	

Time frame: past 36 months

X_None

X__None

_X__None

2

3

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

any entity (if not indicated

		T	1		
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
	•				
7	Support for attending	X None			
,	meetings and/or travel				
	meetings and/or traver				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	xNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
12		V None			
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None.		

D - • •			
	e:Mar. 16 th , 2022 r Name: Jin-Yin Yan	-	
		ovicity monitoring of pyro	tinib in combination with nab-paclitaxel, doxorubicin,
			single-armed clinical trial
			-22-161
	,		
relat part	ted to the content of your miles whose interests may be	nanuscript. "Related" mea affected by the content of	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment
	ansparency and does not no tionship/activity/interest, it		If you are in doubt about whether to list a so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to th	• -	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all suppetime frame for disclosure is	•	I in this manuscript without time limit. For all other items,
		Name all antities with	Specifications/Comments
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	I planning of the work
_		T	
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		- :	25
2		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated	XNone	

in item #1 above).

Royalties or licenses

Consulting fees

X__None

_X__None

		T	1		
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
	•				
7	Support for attending	X None			
,	meetings and/or travel				
	meetings and/or traver				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
9	Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	xNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
12		V None			
13	Other financial or non-	XNone			
	financial interests				
Please summarize the above conflict of interest in the following box:					

None.		

		TOWISE DISCE	SSORE I GRAVI				
	e:Mar. 16 th , 2022	-					
Mar			tinib in combination with nab-paclitaxel, doxorubicin,				
	and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial Manuscript number (if known): GS-22-161						
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.				
	following questions apply to nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>				
to tl	-	nsion, you should declare a	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive me manuscript.				
	em #1 below, report all sup time frame for disclosure is	•	in this manuscript without time limit. For all other items,				
		Name all entities with	Specifications/Comments				
		whom you have this	(e.g., if payments were made to you or to your				
		relationship or indicate	institution)				
		none (add rows as needed)					
		Time frame: Since the initia	l planning of the work				
1	All support for the present	X None					
-	manuscript (e.g., funding,						
	provision of study materials,						
	medical writing, article						
	processing charges, etc.) No time limit for this item.						
	No time inine for tims item.						
		Time frame: past	36 months				
2	Grants or contracts from	X None	- So months				
_	any entity (if not indicated in item #1 above).						

Royalties or licenses

Consulting fees

X__None

X__None

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
6	educational events Payment for expert	X None			
6	testimony	XNOTIE			
	testimony				
7	Support for attending	X None			
	meetings and/or travel				
	G .				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Descipt of annique and	V Name			
12	Receipt of equipment, materials, drugs, medical	X_None			
	writing, gifts or other				
	services				
13	Other financial or non-	X None			
13	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None.

	e:Mar. 16 th , 2022	-	
	r Name: Yong-Ping Lian	-	
			tinib in combination with nab-paclitaxel, doxorubicin,
		-	single-armed clinical trial
Mar	nuscript number (if known):	GS	-22-161
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to th	• -	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	-	l in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	Il planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	Y None	

any entity (if not indicated

X__None

_X__None

in item #1 above).

Royalties or licenses

Consulting fees

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
6	educational events Payment for expert	X None			
6	testimony	XNOTIE			
	testimony				
7	Support for attending	X None			
	meetings and/or travel				
	G .				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Descipt of annique and	V Name			
12	Receipt of equipment, materials, drugs, medical	X_None			
	writing, gifts or other				
	services				
13	Other financial or non-	X None			
13	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None.

	e:Mar. 16 th , 2022	-	
	r Name: Hui-Wen Zhang		
			tinib in combination with nab-paclitaxel, doxorubicin,
		-	single-armed clinical trial
Mar	uscript number (if known):	GS	-22-161
related to the man to the med	ted to the content of your miles whose interests may be cansparency and does not not tionship/activity/interest, it following questions apply touscript only. author's relationships/activite epidemiology of hyperterication, even if that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship wities/interests should be go nsion, you should declare a tion is not mentioned in the	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	I who wing of the world
		Time frame: Since the initia	ai planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	

any entity (if not indicated

X__None

_X__None

in item #1 above).

Consulting fees

Royalties or licenses

3

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
6	educational events Payment for expert	X None			
6	testimony	XNOTIE			
	testimony				
7	Support for attending	X None			
	meetings and/or travel				
	G .				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Descipt of annique and	V Name			
12	Receipt of equipment, materials, drugs, medical	X_None			
	writing, gifts or other				
	services				
13	Other financial or non-	X None			
13	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None.

		TOWISE DISCE	SOURT ONLY
You Mar and	cyclophosphamide in HER2	coxicity monitoring of pyro positive breast cancer: a	otinib in combination with nab-paclitaxel, doxorubicin, single-armed clinical trial
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply touscript only.	o the author's relationshi	ps/activities/interests as they relate to the current
to ti med In it	ne epidemiology of hypertentication, even if that medica	nsion, you should declare ition is not mentioned in to port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other items,
		I	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from	Y None	

any entity (if not indicated

X__None

_X__None

in item #1 above).

Royalties or licenses

Consulting fees

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
6	educational events Payment for expert	X None			
6	testimony	XNOTIE			
	testimony				
7	Support for attending	X None			
	meetings and/or travel				
	G .				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Descipt of annique and	V Name			
12	Receipt of equipment, materials, drugs, medical	X_None			
	writing, gifts or other				
	services				
13	Other financial or non-	X None			
13	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None.

Dat	e:Mar. 16 th , 2022		
	r Name: Hai-feng Cai	• •	
Mai	nuscript Title: Cardiot	oxicity monitoring of pyro	etinib in combination with nab-paclitaxel, doxorubicin,
and	cyclophosphamide in HER2	-positive breast cancer: a	single-armed clinical trial
Maı	nuscript number (if known):	GS	-22-161
rela	ted to the content of your n	nanuscript. "Related" mea	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment
-	-	-	If you are in doubt about whether to list a
	tionship/activity/interest, it	· · · · · · · · · · · · · · · · · · ·	-
	, , , , , , , , , , , , , , , , , , , ,	, ,	
	following questions apply t nuscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
med In it	dication, even if that medica	ntion is not mentioned in t port for the work reported	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other items. Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	X None	
_	manuscript (e.g., funding,		
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	X None	

any entity (if not indicated

X__None

X__None

in item #1 above).
Royalties or licenses

Consulting fees

			,		
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
6	educational events Payment for expert	X None			
ь	testimony	x_none			
	testimony				
7	Support for attending	XNone			
,	meetings and/or travel				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
12	materials, drugs, medical	^_None			
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Please summarize the above conflict of interest in the following box:					

None.	